Citations

Showing 10 of 108094 citations.

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
Noseworthy, Peter A. , Houten, Holly K. Van , Krumholz, Harlan M. , Kent, David M. , Abraham, Neena S. , Graff‐Radford, Jonathan , Alkhouli, Mohamad , Henk, Henry J. , Shah, Nilay D. , Gersh, Bernard J. , Friedman, Paul A. , Holmes, David R. , Van Houten, Holly K , Yao, Xiaoxi , Krumholz, Harlan M. , Alkhouli, Mohamad , Noseworthy, Peter A , Gersh, Bernard J , Kent, David M , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | September 29, 2022 | Volume: 11 | Issue: 19 | Pages: No page available

10.1161/jaha.121.027001 | PMID 36172961 Get It

Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients with atrial fibrillation were identified, among whom 8397 were treated with LAAO and 554 453 were treated with non‐vitamin K antagonist oral anticoagulants between March 13, 2015 and December 31, 2018. Propensity score overlap weighting was used to balance baseline characteristics. The primary outcome was a composite end point of ischemic stroke or systemic embolism, major bleeding, and all‐cause mortality. The mean age was 76.4±7.6 years; 280 097 (49.8%) were female. Mean follow‐up was 1.5±1.0 years. LAAO was associated with no significant difference in the risk of the primary composite end point (hazard ratio [HR], 0.93 [0.84–1.03]), or the secondary outcomes including ischemic stroke/systemic embolism (HR, 1.07 [0.81–1.41]), and intracranial bleeding (HR, 1.08 [0.72–1.61]). LAAO was associated with a higher risk of major bleeding (HR, 1.22 [1.05–1.42], P =0.01) and a lower risk of mortality (HR, 0.73 [0.64–0.84], P <0.001). The lower risk of mortality associated with LAAO was most pronounced in patients with a prior history of intracranial bleeding. Conclusions In comparison to non‐vitamin K antagonist oral anticoagulants, LAAO was associated with no significant difference in the risk of the composite outcome and a lower risk of mortality, which suggests LAAO might be a reasonable option in select patients with atrial fibrillation. The observation of higher bleeding risk associated with LAAO highlights the need to optimize postprocedural antithrombotic regimens as well as systematic efforts to assess and address bleeding predispositions.
Author response: Isometric spiracular scaling in scarab beetles—implications for diffusive and advective oxygen transport
Wagner, Julian M. , Klok, C. Jaco, Duell, Meghan , Socha, John J. , Cao, Guohua , Harrison, Jon F. , Cao, Guohua, Gong, Hao

Mayo Clinic

No container title available | September 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.82129.sa2 Get It

Identifying appropriate comparison groups for health system interventions in the COVID‐19 era
Savitz, Samuel T. , Scott, Jason , Keast, Erin , Savitz, Lucy A., Leo, Michael C.

Mayo Clinic

Learning Health Systems | September 29, 2022 | Volume: 7 | Issue: 2 | Pages: No page available

10.1002/lrh2.10344 | PMID 36247204 Get It

AbstractIntroductionCOVID‐19 has created additional challenges for the analysis of non‐randomized interventions in health system settings. Our objective is to evaluate these challenges and identify lessons learned from the analysis of a medically tailored meals (MTM) intervention at Kaiser Permanente Northwest (KPNW) that began in April 2020.MethodsWe identified both a historical and concurrent comparison group. The historical comparison group included patients living in the same area as the MTM recipients prior to COVID‐19. The concurrent comparison group included patients admitted to contracted non‐KPNW hospitals or admitted to a KPNW facility and living outside the service area for the intervention but otherwise eligible. We used two alternative propensity score methods in response to the loss of sample size with exact matching to evaluate the intervention.ResultsWe identified 452 patients who received the intervention, 3873 patients in the historical comparison group, and 5333 in the concurrent comparison group. We were able to mostly achieve balance on observable characteristics for the intervention and the two comparison groups.ConclusionsLessons learned included: (a) The use of two different comparison groups helped to triangulate results; (b) the meaning of utilization measures changed pre‐ and post‐COVID‐19; and (c) that balance on observable characteristics can be achieved, especially when the comparison groups are meaningfully larger than the intervention group. These findings may inform the design for future evaluations of interventions during COVID‐19.
“Nothing burns like the cold”: Cardiovascular disease in frigid zones
Lerman, Ben , Lerman, Lilach O.

Mayo Clinic

Frigid Zone Medicine | September 29, 2022 | Volume: 2 | Issue: 3 | Pages: 129-131

10.2478/fzm-2022-0017 Get It

Healthcare Providers’ Experiences with Hiccups in Patients with Cancer: Report of a United States National Survey
Wieland, Jana, Martin, Nichole , Jatoi, Aminah

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | September 29, 2022 | Volume: 40 | Issue: 8 | Pages: 872-880

10.1177/10499091221130042 | PMID 36172916 Get It

Hiccups occur in 15-40% of cancer patients, but previous research has not sought the perspectives of cancer healthcare providers. The objective of this research is to report on United States cancer healthcare providers’ awareness of their patients’ hiccups and these healthcare providers' perceived need for further palliation options. A survey was developed and then distributed throughout the United States via email to cancer healthcare providers; results are reported descriptively. Six hundred eighty-four cancer healthcare providers completed 2 eligibility screening questions which required them to have cared for an adequate number of patients (> 10 in the past 6 months) with “clinically significant” hiccups (defined as hiccups that persisted for >48 hours or occurred from cancer or from cancer care). Of 113 eligible healthcare providers, 90 completed the survey. Healthcare providers described hiccups as associated with stress/anxiety, fatigue, sleep problems, and decreased work/school productivity. In 49% of patients, healthcare providers initially prescribed medications (commonly chlorpromazine or baclofen); 18% expressed dissatisfaction with current palliation. Proffered comments included, “When current therapies do not work, it can be very demoralizing to our patients; ” and “…my biggest complaint is that current treatments also come with their own side effects which can be quite severe.” Discordance appears to exist between the percentage of cancer patients with hiccups and the percentage of cancer healthcare providers with awareness of their patients’ hiccups. Nonetheless, healthcare providers described notable hiccup-associated symptoms in their patients and a need for more palliative options.
DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer
Yu, Huichuan , Wang, Xiaolin , Tang, Guannan , Cui, Ji , Ding, Yanqing , Cai, Muyan , Huang, Meijin , Gallinger, Steven , Pai, Rish K. , Win, Aung Ko , Wang, Jianping , Luo, Yanxin , Cao, Guangwen , Pai, R K , Luo, Yanxin , Win, Aung K , Yu, Huichuan , Bai, Liangliang , Carter, Kelly , Huang, Pinzhu , Li, Liang , Liu, Huanliang , Cao, Guangwen , Buchanan, Daniel D. , Newcomb, Polly A. , Grady, William M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 29, 2022 | Volume: 115 | Issue: 1 | Pages: 52-61

10.1093/jnci/djac183 | PMID 36171645 Get It

AbstractBackgroundThe current risk stratification system defined by clinicopathological features does not identify the risk of recurrence in early-stage (stage I-II) colorectal cancer (CRC) with sufficient accuracy. We aimed to investigate whether DNA methylation could serve as a novel biomarker for predicting prognosis in early-stage CRC patients.MethodsWe analyzed the genome-wide methylation status of CpG loci using Infinium MethylationEPIC array run on primary tumor tissues and normal mucosa of early-stage CRC patients to identify potential methylation markers for prognosis. The machine-learning approach was applied to construct a DNA methylation–based prognostic classifier for early-stage CRC (MePEC) using the 4 gene methylation markers FAT3, KAZN, TLE4, and DUSP3. The prognostic value of the classifier was evaluated in 2 independent cohorts (n = 438 and 359, respectively).ResultsThe comprehensive analysis identified an epigenetic subtype with high risk of recurrence based on a group of CpG loci in the CpG-depleted region. In multivariable analysis, the MePEC classifier was independently and statistically significantly associated with time to recurrence in validation cohort 1 (hazard ratio = 2.35, 95% confidence interval = 1.47 to 3.76, P &lt; .001) and cohort 2 (hazard ratio = 3.20, 95% confidence interval = 1.92 to 5.33, P &lt; .001). All results were further confirmed after each cohort was stratified by clinicopathological variables and molecular subtypes.ConclusionsWe demonstrated the prognostic statistical significance of a DNA methylation profile in the CpG-depleted region, which may serve as a valuable source for tumor biomarkers. MePEC could identify an epigenetic subtype with high risk of recurrence and improve the prognostic accuracy of current clinical variables in early-stage CRC.
Apoptotic Body-Rich Media from Tenocytes Enhance Proliferation and Migration of Tenocytes and Bone Marrow Stromal Cells
Dong, Chenhui, Gingery, Anne , Amadio, Peter C. , An, Kai‐Nan, Moran, Steven L. , Zhao, Chunfeng , Zhao, Chunfeng , Gingery, Anne

Mayo Clinic

International Journal of Molecular Sciences | September 29, 2022 | Volume: 23 | Issue: 19 | Pages: 11475

10.3390/ijms231911475 | PMID 36232777 Get It

The intrinsic healing following tendon injury is ideal, in which tendon progenitor cells proliferate and migrate to the injury site to directly bridge or regenerate tendon tissue. However, the mechanism determining why and how those cells are attracted to the injury site for tendon healing is not understood. Since the tenocytes near the injury site go through apoptosis or necrosis following injury, we hypothesized that secretions from injured tenocytes might have biological effects on cell proliferation and migration to enhance tendon healing. Tenocyte apoptosis was induced by 24 h cell starvation. Apoptotic body-rich media (T-ABRM) and apoptotic body-depleted media (T-ABDM) were collected from culture media after centrifuging. Tenocytes and bone marrow-derived stem cells (BMDSCs) were isolated and cultured with the following four media: (1) T-ABRM, (2) T-ABDM, (3) GDF-5, or (4) basal medium with 2% fetal calf serum (FCS). The cell activities and functions were evaluated. Both T-ABRM and T-ABDM treatments significantly stimulated the cell proliferation, migration, and extracellular matrix synthesis for both tenocytes and BMDSCs compared to the control groups (GDF-5 and basal medium). However, cell proliferation, migration, and extracellular matrix production of T-ABRM-treated cells were significantly higher than the T-ABDM, which indicates the apoptotic bodies are critical for cell activities. Our study revealed the possible mechanism of the intrinsic healing of the tendon in which apoptotic bodies, in the process of apoptosis, following tendon injury promote tenocyte and stromal cell proliferation, migration, and production. Future studies should analyze the components of the apoptotic bodies that play this role, and, thus, the targeting of therapeutics can be developed.
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
Aggarwal, Rahul , Alumkal, Joshi J. , Higano, Celestia S. , Bryce, Alan H. , Lopez‐Gitlitz, Angela , McCarthy, Sharon , Miladinović, Branko, McQuarrie, Kelly , Thomas, Shibu , Zhang, Ke , Bryce, Alan H , Szmulewitz, Russell Z , Small, Eric J.

Mayo Clinic

Prostate Cancer | September 29, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-12

10.1155/2022/5454727 | PMID 36212187 Get It

Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). Mean changes from baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) at 12 months (primary endpoint) and other prespecified assessments of health-related quality of life (HRQoL), PSA nadir, time to PSA progression, time to testosterone recovery, recovered testosterone >150 ng/dL without PSA progression at 24 months, and molecular markers were evaluated. Results. In 90 enrolled patients (apalutamide plus ADT (n = 31), apalutamide (n = 29), ADT (n = 30)), FACT-P at 12 months was not significantly different between apalutamide, ADT and apalutamide, and ADT groups. Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23–1.36, P = 0.196 ); time to testosterone recovery was similar in the ADT-containing groups. In apalutamide plus ADT, apalutamide, and ADT groups, 37.9%, 37.0%, and 19.2% of patients, respectively, had testosterone >150 ng/dL at 24 months without confirmed PSA progression. Of the few biomarkers expressed in blood, EPHA3 was significantly associated with shorter time to PSA progression ( P = 0.02 ) in the overall population. Conclusions. HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.
The American Foregut Society White Paper on the Endoscopic Classification of Esophagogastric Junction Integrity
Nguyen, Ninh T. , Chang, Kenneth J. , Lipham, John C. , Dayyeh, Barham Abu, Wilson, Erik B., Muthusamy, V. Raman, Bell, Reginald , Janu, Peter , Runge, Ava , Thosani, Nirav C , Canto, Marcia Irene , Muthusamy, V. Raman , Clarke, John O. , Swanström, Lee L. , Kahrilas, Peter J.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | September 29, 2022 | Volume: 2 | Issue: 4 | Pages: 339-348

10.1177/26345161221126961 Get It

Background: The American Foregut Society (AFS) is dedicated to advancing patient care and digestive health within the realm of foregut disease. One of the most common and debilitating esophageal conditions is gastroesophageal reflux disease (GERD). The Hill grade is an endoscopic classification of the esophagogastric junction (EGJ) based on the appearance of the gastroesophageal flap valve from a retroflexed view of the hiatus. This endoscopic classification provides insight into the anatomic disruption of the EGJ which has been shown to correlate with GERD. However, clinical utilization of this classification by endoscopists has been limited due to the perceived relevance and subjectivity of the classification. With the advent of endoscopic treatment options for GERD, there is renewed enthusiasm to develop a grading system of the EGJ that can objectively define anatomical impairment and reduce interobserver grading variability. Methods: The AFS convened a 13-member working group tasked with reviewing the Hill grade classification and formulating a proposal for its revision utilizing a modified Delphi method. This white paper summarizes the output from this working group. Results: The working group concluded that all components of the antireflux barrier—the lower esophageal sphincter and its sling fibers, the crural diaphragm, and the gastroesophageal flap valve—contribute to EGJ integrity. Using defined objective parameters of extent of hiatal axial herniation and crural disruption and presence or absence of a flap valve, the new AFS classification stratifies EGJ integrity from normal (grade 1) to increasing degrees of EGJ disruption (grade 2-4) beginning with loss of the flap valve and progressing to increasing degrees of crural disruption and hiatus hernia. This AFS classification also stipulates appropriate endoscopic methodology to utilize in making the assessment and provides a basic nomenclature for communication among endoscopists. Conclusions: The AFS endoscopic classification of the EGJ expands on the Hill classification by including assessment of axial hiatal hernia length (L), hiatal aperture diameter (D), and presence or absence of the flap valve (F) making it more comprehensive - LDF components. Future directions include validation studies correlating the ability of the AFS classification in predicting the presence and severity of GERD.
Does Ultrasound Guidance Improve the Effectiveness of Neurotoxin Injections in Patients with Cervical Dystonia? (A Prospective, Partially-Blinded, Clinical Study)
Tyślerowicz, Małgorzata , Dulski, Jarosław , Gawryluk, Justyna , Dulski, Jaroslaw , Sławek, Jarosław

Mayo Clinic

Toxins | September 29, 2022 | Volume: 14 | Issue: 10 | Pages: 674

10.3390/toxins14100674 | PMID 36287943 Get It

Aim: The aim of this study was to evaluate the efficacy of ultrasound guidance (US) in the treatment of cervical dystonia (CD) with botulinum neurotoxin type A (BoNT-A) injections in comparison to anatomical landmarks (AL). To date, US is routinely used in many centers, but others deny its usefulness. Materials and Methods: Thirty-five patients (12 males, 23 females) with a clinical diagnosis of CD were included in the study. Intramuscular administration of BoNT-A was performed using either US guidance, or with AL, in two separate therapeutic sessions. The efficacy of BoNT-A administration was assessed with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Tsui modified scale, Craniocervical Dystonia Questionnaire (CDQ-24) and Clinical Global Impression—Improvement scale (CGI-I). Additionally, patients at therapeutic sessions were digitally recorded and evaluated by two blinded and independent raters. Results: A significant decrease in total TWSTRS, severity subscale TWSTRS, Tsui score, and CDQ-24 was found in both the AL and US group; however, in the TWSTRS disability and pain subscales, a significant decrease was found only in the US group. Moreover, US guided treatment also resulted in a greater decrease in TWSTRS, Tsui score and CDQ-24 compared to anatomical landmarks use only. Conclusions: US guidance might be helpful in improving the results of BoNT-A injections in cervical dystonia, reducing associated pain and disability; however, more studies are needed to evaluate its clinical efficacy.